GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
暂无分享,去创建一个
[1] W. Rocchia,et al. SiteFerret: Beyond Simple Pocket Identification in Proteins , 2022, Journal of chemical theory and computation.
[2] Simone Brogi,et al. Front Cover: Synthesis of Unsymmetrical Squaramides as Allosteric GSK‐3β Inhibitors Promoting β‐Catenin‐Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial Cells (ChemMedChem 24/2022) , 2022, ChemMedChem.
[3] A. Cavalli,et al. Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays , 2022, International journal of molecular sciences.
[4] M. Racchi,et al. Molecular Characterization of Membrane Steroid Receptors in Hormone-Sensitive Cancers , 2021, Cells.
[5] L. Federico,et al. Revisiting the Proposition of Binding Pockets and Bioactive Poses for GSK-3β Allosteric Modulators Addressed to Neurodegenerative Diseases , 2021, International journal of molecular sciences.
[6] A. Rico,et al. Allosteric Modulation of GSK-3β as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related , 2021, International journal of molecular sciences.
[7] R. Lewis,et al. Fragment-Based Discovery of Novel Allosteric MEK1 Binders. , 2021, ACS medicinal chemistry letters.
[8] J. Bajorath,et al. Structure- and Similarity-Based Survey of Allosteric Kinase Inhibitors, Activators, and Closely Related Compounds. , 2021, Journal of medicinal chemistry.
[9] H. Senderowitz,et al. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site , 2020, International journal of molecular sciences.
[10] E. J. de la Rosa,et al. Dynamics of Central Remyelination and Treatment Evolution in a Model of Multiple Sclerosis with Optic Coherence Tomography , 2020, bioRxiv.
[11] Carlos Roca,et al. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019) , 2020, Expert opinion on therapeutic patents.
[12] T. Minamoto,et al. Glycogen Synthase Kinase 3β in Cancer Biology and Treatment , 2020, Cells.
[13] Yajie Yang,et al. Inhibition of glycogen synthase kinase 3β improves cognitive function in aged mice by upregulating claudin presences in cerebral endothelial cells. , 2020, Acta biochimica et biophysica Sinica.
[14] F. Schwartz,et al. Identification of a Novel Selective and Potent Inhibitor of Glycogen Synthase Kinase-3. , 2019, American journal of physiology. Cell physiology.
[15] D. Koehler,et al. The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease , 2019, Neurochemistry International.
[16] Sergio Decherchi,et al. NanoShaper–VMD interface: computing and visualizing surfaces, pockets and channels in molecular systems , 2018, Bioinform..
[17] E. J. de la Rosa,et al. GSK-3 Inhibitors: From the Brain to the Retina and Back Again. , 2019, Advances in experimental medicine and biology.
[18] S. Nagini,et al. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer. , 2019, Seminars in cancer biology.
[19] Huan Yang,et al. GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors , 2018, Nature Communications.
[20] Hsin-Yi Chang,et al. Manzamine A Exerts Anticancer Activity against Human Colorectal Cancer Cells , 2018, Marine drugs.
[21] E. J. de la Rosa,et al. Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa , 2018, Molecular Neurodegeneration.
[22] R. Mancinelli,et al. Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases , 2017, Oxidative medicine and cellular longevity.
[23] Linfu Li,et al. The Key Roles of GSK-3β in Regulating Mitochondrial Activity , 2017, Cellular Physiology and Biochemistry.
[24] E. Hur,et al. Differential Roles of Glycogen Synthase Kinase 3 Subtypes Alpha and Beta in Cortical Development , 2017, Front. Mol. Neurosci..
[25] B. Sepodes,et al. Thiadiazolidinone-8 Ameliorates Inflammation Associated with Experimental Colitis in Mice , 2017, Pharmacology.
[26] A. Stranahan,et al. Glucocorticoid-mediated activation of GSK3β promotes tau phosphorylation and impairs memory in type 2 diabetes , 2017, Neurobiology of Aging.
[27] W. Rocchia,et al. Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis , 2017, ACS central science.
[28] Deyong Ye,et al. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer. , 2017, European journal of medicinal chemistry.
[29] L. Rubin,et al. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases. , 2017, Journal of medicinal chemistry.
[30] Ather Muneer. Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications , 2017, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.
[31] Ana Martínez,et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis , 2017, Scientific Reports.
[32] Steven P. Miller,et al. GSK‐3β inhibitor TDZD‐8 reduces neonatal hypoxic‐ischemic brain injury in mice , 2017, CNS neuroscience & therapeutics.
[33] J. Thornton,et al. Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease , 2017, PLoS genetics.
[34] H. Hamid,et al. Natural and synthetic bioactive inhibitors of glycogen synthase kinase. , 2017, European journal of medicinal chemistry.
[35] Navneet Chauhan,et al. Classifying druggability on potential binding sites of glycogen synthase kinase-3?: an in-silico assessment , 2017 .
[36] J. Woodgett,et al. Glycogen Synthase Kinase 3: A Kinase for All Pathways? , 2017, Current topics in developmental biology.
[37] Navneet Chauhan,et al. Pharmacophore feature-based virtual screening for finding potent GSK-3 inhibitors using molecular docking and dynamics simulations , 2016, Bioinformation.
[38] M. Eisenstein,et al. A unique type of GSK-3 inhibitor brings new opportunities to the clinic , 2016, Science Signaling.
[39] I. Roy,et al. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors. , 2016, European journal of medicinal chemistry.
[40] R. Barker,et al. GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte–neuron interactions , 2016, Cell Death and Disease.
[41] Haiyan Zhou,et al. Inhibition of GSK-3β Alleviates Collagen II-Induced Rheumatoid Arthritis in Rats , 2016, Medical science monitor : international medical journal of experimental and clinical research.
[42] Cheng-Long Xie,et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats , 2016, Scientific Reports.
[43] J. Lucas,et al. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. , 2015, Human molecular genetics.
[44] R. Jope,et al. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. , 2015, Pharmacology & therapeutics.
[45] N. Ibrahim,et al. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. , 2015, Pharmacological research.
[46] J. Goudreau,et al. GSK-3β dysregulation contributes to parkinson’s-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein , 2014, Cell Death and Differentiation.
[47] J. Woodgett,et al. Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis , 2013, Oncogene.
[48] B. Dubois,et al. A phase II trial of tideglusib in Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.
[49] Deyong Ye,et al. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake. , 2014, Bioorganic & medicinal chemistry letters.
[50] A. Hannan,et al. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. , 2014, Human molecular genetics.
[51] Xinyu Wang,et al. Oncotargets and Therapy Dovepress Clinicopathological and Biological Significance of Aberrant Activation of Glycogen Synthase Kinase-3 in Ovarian Cancer , 2022 .
[52] J. Ávila,et al. GSK-3β, a pivotal kinase in Alzheimer disease , 2014, Front. Mol. Neurosci..
[53] Stephen L. Abrams,et al. GSK-3 as potential target for therapeutic intervention in cancer , 2014, Oncotarget.
[54] E. Tolosa,et al. A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy , 2014, Movement disorders : official journal of the Movement Disorder Society.
[55] H. Huppertz,et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial , 2014, Movement disorders : official journal of the Movement Disorder Society.
[56] Wei Chen,et al. Association of glycogen synthase kinase-3β with Parkinson’s disease (Review) , 2014, Molecular medicine reports.
[57] E. Novellino,et al. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors. , 2013, Journal of medicinal chemistry.
[58] Deyong Ye,et al. Design, Synthesis and Biological Evaluation of Benzothiazepinones (BTZs) as Novel Non‐ATP Competitive Inhibitors of Glycogen Synthase Kinase‐3β (GSK‐3β). , 2013 .
[59] J. Woodgett,et al. Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3 , 2013, The Journal of Immunology.
[60] Sergio Decherchi,et al. A general and Robust Ray-Casting-Based Algorithm for Triangulating Surfaces at the Nanoscale , 2013, PloS one.
[61] P. Zhang,et al. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β). , 2013, European journal of medicinal chemistry.
[62] M. Lodish. Kinase Inhibitors: Adverse Effects Related to the Endocrine System , 2013 .
[63] F. J. Luque,et al. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. , 2013, European journal of medicinal chemistry.
[64] David J. Fleet,et al. Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.
[65] P. Zhang,et al. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening. , 2012, Bioorganic & medicinal chemistry letters.
[66] R. Jope,et al. Glycogen synthase kinase‐3 levels and phosphorylation undergo large fluctuations in mouse brain during development , 2012, Bipolar disorders.
[67] D. Hedley,et al. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to TRAIL-Induced Apoptosis , 2012, PloS one.
[68] V. Bilim,et al. GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC). , 2012, Biochemical and biophysical research communications.
[69] C. Pérez,et al. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. , 2012, Journal of medicinal chemistry.
[70] Miguel Medina,et al. Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib* , 2011, The Journal of Biological Chemistry.
[71] C. Pérez,et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. , 2011, Journal of medicinal chemistry.
[72] Ana Martínez,et al. GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS , 2011, Front. Mol. Neurosci..
[73] R. Belmaker,et al. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. , 2011, Current pharmaceutical design.
[74] Benyi Li,et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo , 2011, The Prostate.
[75] F. J. Luque,et al. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. , 2011, Journal of medicinal chemistry.
[76] A. Bush,et al. GSK-3 in Neurodegenerative Diseases , 2011, International journal of Alzheimer's disease.
[77] M. Eisenstein,et al. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor. , 2011, Journal of molecular biology.
[78] Y. Fall,et al. An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors. , 2011, European journal of medicinal chemistry.
[79] J. Roder,et al. Genetic and pharmacological evidence for schizophrenia‐related Disc1 interaction with GSK‐3 , 2011, Synapse.
[80] A. Wright,et al. A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis , 2011, Investigational New Drugs.
[81] Weiguo Lu,et al. Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells With Acquired Paclitaxel Resistance , 2010, International Journal of Gynecologic Cancer.
[82] A. Pérez-Castillo,et al. Inhibition of Glioblastoma Growth by the Thiadiazolidinone Compound TDZD-8 , 2010, PloS one.
[83] D. Osolodkin,et al. Interaction of manzamine A with glycogen synthase kinase 3β: a molecular dynamics study , 2010 .
[84] J. Sweatt,et al. Deficiency in the Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3 Increases Sensitivity to Mood Disturbances , 2010, Neuropsychopharmacology.
[85] R. J. Doerksen,et al. Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. , 2010, Journal of medicinal chemistry.
[86] F. J. Luque,et al. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. , 2009, Bioorganic & medicinal chemistry.
[87] T. Gómez-Isla,et al. A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo , 2009, Neurobiology of Disease.
[88] T. Duka,et al. α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[89] Yongzhou Hu,et al. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors. , 2009, Bioorganic & medicinal chemistry.
[90] Y. Fall,et al. The first enantioselective synthesis of palinurin. , 2009, Chemical communications.
[91] Simon Lovestone,et al. The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.
[92] Xiaojie Li,et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). , 2007, Blood.
[93] K. Kawakami,et al. Inhibition of GSK‐3β activity attenuates proliferation of human colon cancer cells in rodents , 2007, Cancer science.
[94] Ana Martínez,et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. , 2007, Journal of natural products.
[95] A. Dennison,et al. Glycogen synthase kinase-3 beta; a new target in pancreatic cancer? , 2007, Current cancer drug targets.
[96] M. Medina,et al. P4-335 Glycogen synthase kinase-3β inhibitors from marine origin , 2006, Alzheimer's & Dementia.
[97] Xin Lu,et al. Glycogen synthase kinase-3β positively regulates the proliferation of human ovarian cancer cells , 2006, Cell Research.
[98] B. Tekwani,et al. Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases. , 2006, Journal of natural products.
[99] J. C. Ghosh,et al. Activation of p53-Dependent Apoptosis by Acute Ablation of Glycogen Synthase Kinase-3β in Colorectal Cancer Cells , 2005, Clinical Cancer Research.
[100] C. Thiele,et al. Glycogen synthase kinase 3β (GSK3β) mediates 6‐ hydroxydopamine‐induced neuronal death , 2004 .
[101] S. Wahyuono,et al. New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. , 2004, Journal of medicinal chemistry.
[102] T. Sotnikova,et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[103] C. Pérez,et al. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching. , 2003, Journal of medicinal chemistry.
[104] J. Paramio,et al. Expression, localization, and activity of glycogen synthase kinase 3β during mouse skin tumorigenesis , 2002, Molecular carcinogenesis.
[105] C. Pérez,et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.
[106] F. J. Luque,et al. Classical molecular interaction potentials: Improved setup procedure in molecular dynamics simulations of proteins , 2001, Proteins.
[107] Laurence H. Pearl,et al. Crystal Structure of Glycogen Synthase Kinase 3β Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition , 2001, Cell.
[108] J. Baños,et al. N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. , 2000, European journal of medicinal chemistry.
[109] J. Palacios,et al. Arylimino-1,2,4-thiadiazolidinones: a new family of potassium channel openers. , 1997, Bioorganic & medicinal chemistry.
[110] R. Sakai,et al. Manzamine A, a novel antitumor alkaloid from a sponge , 1986 .